6,000 Shares in Insulet Corporation $PODD Acquired by Icon Advisers Inc. Co.

Icon Advisers Inc. Co. bought a new stake in shares of Insulet Corporation (NASDAQ:PODD) during the 1st quarter, HoldingsChannel.com reports. The firm bought 6,000 shares of the medical instruments supplier’s stock, valued at approximately $1,259,000.

A number of other hedge funds also recently modified their holdings of PODD. Glenmede Investment Management LP boosted its position in shares of Insulet by 1.6% in the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock worth $708,000 after buying an additional 35 shares during the period. Curi Capital LLC lifted its stake in Insulet by 0.8% in the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after acquiring an additional 36 shares in the last quarter. Great Lakes Advisors LLC boosted its position in Insulet by 1.5% during the 4th quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock worth $791,000 after acquiring an additional 40 shares during the period. Camarda Financial Advisors LLC boosted its position in Insulet by 0.5% during the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock worth $2,304,000 after acquiring an additional 40 shares during the period. Finally, Larson Financial Group LLC grew its stake in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares in the last quarter.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of research reports. Benchmark reiterated a “buy” rating on shares of Insulet in a report on Wednesday, May 27th. Truist Financial decreased their price target on shares of Insulet from $219.00 to $210.00 and set a “buy” rating for the company in a report on Monday, July 13th. Robert W. Baird lowered their price objective on shares of Insulet from $360.00 to $248.00 in a research report on Thursday, May 7th. Citigroup upped their price objective on shares of Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Finally, Wells Fargo & Company cut their target price on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Twenty-two analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $235.25.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Negative Sentiment: Multiple law firms announced or reminded investors about a recently filed securities fraud class action against Insulet, with claims tied to alleged misstatements about Omnipod safety and manufacturing practices. The filings cite two recalls affecting millions of pods and say the issues may have hurt investors who bought shares during the class period. Article Title
• Negative Sentiment: The lawsuit coverage suggests investors are still digesting the fallout from prior recalls and related stock declines, and firms are encouraging shareholders to seek lead-plaintiff roles before the August 31 deadline. Article Title
• Neutral Sentiment: One item noted that analysts still expect double-digit earnings growth ahead of Insulet’s next quarterly report, which provides a potential longer-term offset to the legal headlines. Article Title

Insulet Stock Performance

Shares of PODD stock opened at $158.93 on Thursday. Insulet Corporation has a fifty-two week low of $138.79 and a fifty-two week high of $354.88. The stock’s 50-day moving average is $153.58 and its two-hundred day moving average is $203.76. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The firm has a market cap of $11.01 billion, a P/E ratio of 36.96, a PEG ratio of 1.14 and a beta of 1.11.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm’s revenue was up 33.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Analysts predict that Insulet Corporation will post 6.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of Insulet stock in a transaction on Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the purchase, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.36% of the company’s stock.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.